Literature DB >> 6427998

Adoptive immunization against an established tumor with cytolytic versus memory T cells. Immediate versus delayed onset of regression.

E S Dye, R J North.   

Abstract

Intradermal injection of an admixture of P815 tumor cells and Corynebacterium parvum results in the emergence of a tumor that grows progressively for 9-10 days and then undergoes complete regression. Tumor regression is preceded by a cytolytic T cell response in the spleen that peaks on day 10 and then undergoes progressive decay until days 15-16 when cytolytic T cells can no longer be detected. Passive transfer of 10-day or 30-day spleen cells to T-cell-deficient recipients bearing a 4-day tumor resulted in complete tumor regression. However, whereas passively transferred 10 day spleen cells caused the onset of tumor regression within 2 days, passively transferred 30-day spleen cells did not cause tumor regression until after a 6-8-day delay. Again, the antitumor function of 10-day spleen cells could be eliminated by treatment with cyclophosphamide and vinblastine sulfate, whereas 30 day spleen cells were resistant to both agents. These results indicate that 10-day spleen cells are physiologically different from 30-day spleen cells. The results are consistent with the interpretation that passively transferred 10-day spleen cells cause rapid onset of tumor regression because they are cytolytic T cells and have an immediate capacity to destroy the tumor. In contrast, 30-day spleen cells are helper or memory T cells with no capacity at the time of transfer to destroy the tumor.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6427998     DOI: 10.1097/00007890-198406000-00015

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  11 in total

1.  Ly 1+2- suppressor T cells down-regulate the generation of Ly 1-2+ effector T cells during progressive growth of the P815 mastocytoma.

Authors:  R J North; E S Dye
Journal:  Immunology       Date:  1985-01       Impact factor: 7.397

2.  The therapeutic significance of concomitant antitumor immunity. I. LY-1-2+ T cells from mice with a progressive tumor can cause regression of an established tumor in gamma-irradiated recipients.

Authors:  R J North
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

3.  Cyclophosphamide and abrogation of tumor-induced suppressor T cell activity.

Authors:  S K Hoover; S K Barrett; T M Turk; T C Lee; H D Bear
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma.

Authors:  R J North; M Awwad
Journal:  Immunology       Date:  1990-09       Impact factor: 7.397

5.  Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells.

Authors:  Hiroaki Tanaka; Hironori Matsushima; Norikatsu Mizumoto; Akira Takashima
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

6.  Subtherapeutic numbers of tumour-sensitized, L3T4+, Ly 1+2- T cells are needed for endotoxin to cause regression of an established immunogenic tumour.

Authors:  A Digiacomo; R J North
Journal:  Immunology       Date:  1987-03       Impact factor: 7.397

7.  Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden.

Authors:  M Awwad; R J North
Journal:  Immunology       Date:  1988-09       Impact factor: 7.397

8.  Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity.

Authors:  M Awwad; R J North
Journal:  J Exp Med       Date:  1988-12-01       Impact factor: 14.307

9.  Effect of murine interferon alpha/beta on tumour-induced suppressor function.

Authors:  D M Sahasrabudhe; J C Dusel
Journal:  Cancer Immunol Immunother       Date:  1994-12       Impact factor: 6.968

10.  Inhibition of suppressor T lymphocytes by murine interferon beta.

Authors:  D M Sahasrabudhe
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.